C21 · Pharmaceuticals · China

Innovative drug out-licensing deal value

China: 130 billion USD in 2025, +150.5% on 2024.

  • 130 billion USD Latest · China · 2025
  • +150.5% vs 2024
  • Annual Release cadence
  • 5 Records · 1 region · 2024–2025

Verified 17 Sep 2026 · 2 publishers · Next period 2026

Over time

China over time. Forecasts are dashed with hollow markers; the underlying values are one click away under the chart.

Fig 1 · C21 · China Annual

Innovative drug out-licensing deal value

China, 2024 to 2025

2 observations · 2024 to 2025
Innovative drug out-licensing deal valueInnovative drug out-licensing deal value. 2 observations from 2024 to 2025, ranging from 51.9 billion USD to 130 billion USD. Latest value 130 billion USD (2025). billion USD 0 30 60 90 120 150 2024 2025 51.9 130
Innovative drug out-licensing deal valueInnovative drug out-licensing deal value. 2 observations from 2024 to 2025, ranging from 51.9 billion USD to 130 billion USD. Latest value 130 billion USD (2025). billion USD 0 50 100 150 2024 2025 51.9 130
Innovative drug out-licensing deal valueInnovative drug out-licensing deal value. 2 observations from 2024 to 2025, ranging from 51.9 billion USD to 130 billion USD. Latest value 130 billion USD (2025). billion USD 0 50 100 150 2024 2025 51.9 130
View the underlying data
Innovative drug out-licensing deal value
Period Type Value
2024 Actual 51.9 billion USD
2025 Actual 130 billion USD
Source: NHSA · billion USD · CC BY 4.0 · statorigin.org

Every record

5 records · 1 region · 2024–2025. Each period links to its record: the value, its source evidence and original document.

Innovative drug out-licensing deal value: every record, grouped by region, newest first.
Period Value Source Type
China 5 records
2025 130 billion USD NHSA · 31 Dec 2025
2025 130 billion USD NHSA · 31 Dec 2025
2025 135.7 billion USD MOFCOM · 31 Dec 2025
2024 51.9 billion USD MOFCOM · 31 Dec 2024
2024 51.9 billion USD NHSA · 31 Dec 2024

Download this data

Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: NHSA and MOFCOM. Licence: CC BY 4.0.

Embed this chart

For automatic sizing and multiple charts, see the JavaScript embed guide.

Free to embed anywhere, including commercially. The attribution bar is part of the chart. The link under the frame is optional: keep it, remove it or mark it rel="nofollow".

<iframe src="https://statorigin.org/embed/pharmaceuticals--innovative-drug-out-licensing-deal-value--trend" width="100%" height="380" style="border:1px solid #e2e5e3;border-radius:8px" title="Innovative drug out-licensing deal value" loading="lazy"></iframe>
<p><a href="https://statorigin.org/indicators/innovative-drug-out-licensing-deal-value">Data: NHSA via StatOrigin</a> · CC BY 4.0</p>
Preview embed

Use and publication rights

  • View, cite and link: free

    Quote any number, cite this page or a single record, and link to it anywhere.

  • Copy, chart and republish: free with attribution

    The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (NHSA and MOFCOM); the chart files already carry that line.

  • The source documents: the publisher's terms

    Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.

How this measure is built

Definition
Total monetary value of out-licensing agreements signed for innovative pharmaceutical products.
Measure
One slice of Out-licensing deal value ( form: level, segment: innovative ) . Total monetary value of out-licensing agreements signed for pharmaceutical assets. Region and period are columns on every record, not slices.
Limitations
Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
Verification
Each value, unit, period and place was checked against its source evidence before publication. See the methodology and the corrections process.

Sources · 3 documents

Other slices of out-licensing deal value

Frequently asked questions

What is the latest innovative drug out-licensing deal value?

China: 130 billion USD in 2025, +150.5% on 2024.

Where does this data come from?

From 3 documents published by NHSA and MOFCOM. Every figure on this page links to its record, which preserves the original source evidence.

How often is it updated?

Annual. The newest published period is 2025; the next release should cover 2026. A new figure appears here once the publisher releases it and it passes verification.

Can I use this data?

Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.

Cite this page

Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.

StatOrigin. (2026). Innovative drug out-licensing deal value [Data set]. Retrieved October 28, 2026, from https://statorigin.org/indicators/innovative-drug-out-licensing-deal-value

"Innovative drug out-licensing deal value." StatOrigin, 2026, https://statorigin.org/indicators/innovative-drug-out-licensing-deal-value. Accessed 28 Oct. 2026.

StatOrigin. "Innovative drug out-licensing deal value." Data set, 2026. Accessed October 28, 2026. https://statorigin.org/indicators/innovative-drug-out-licensing-deal-value.

@misc{statorigin_innovative_drug_out_licensing_deal_value_2026, title = {Innovative drug out-licensing deal value}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/innovative-drug-out-licensing-deal-value}, note = {Data set. Accessed 2026-10-28} }